女性与少数族裔药物洗脱支架术后1年结局:PLATINUM Diversity与PROMUS Element Plus汇总分析
该汇总分析纳入4182例接受依维莫司洗脱支架PCI的患者,比较女性及少数族裔与白人男性的1年结局。女性及少数族裔1年MACE粗率与白人男性相似,但校正后死亡/MI风险更高,主要源于非支架相关MI;社会健康决定因素(如丧偶、缺乏私人保险)独立预测MACE。
要点
- 女性及少数族裔1年MACE粗率与白人男性相似,但校正后死亡/MI风险显著升高。
- 少数族裔校正后MI风险更高,差异主要由非支架相关MI驱动。
- 丧偶和缺乏私人保险等社会因素独立预测女性及少数族裔的1年MACE。
核心结论
- 女性及少数族裔接受依维莫司洗脱支架PCI后1年MACE风险与白人男性相似,但校正后复发性缺血事件风险更高,主要归因于非支架相关MI。
- 临床、造影因素及社会健康决定因素(包括丧偶和保险状态)共同影响女性及少数族裔的1年MACE。
研究设计与样本
- PLATINUM Diversity为单臂研究,纳入女性和少数族裔,收集社会健康决定因素和语言数据,共1501例患者来自52个美国中心。
- 预设与PROMUS Element Plus Post-Approval Study进行患者水平汇总,该研究纳入2681例患者来自52个美国中心(部分中心重叠),为all-comers人群。
- 汇总研究共4182例患者:白人男性1635例(39.1%),女性(白人和少数族裔)1863例(44.5%),少数族裔(女性和男性)1059例(25.3%)。
- 所有患者自2014年10月开始入组,随访12个月,分析自2016年8月开始。
主要发现
- 未校正1年MACE率:白人男性7.6%,女性8.6%,少数族裔9.6%,组间无显著差异,风险校正后亦无显著差异。
- 校正后死亡/MI风险:女性OR 1.6(95%CI 1.1-2.4),少数族裔OR 1.9(95%CI 1.2-2.8),均高于白人男性。
- 校正后MI风险:少数族裔OR 2.6(95%CI 1.4-4.8),高于白人男性。
- 上述差异主要由非支架相关MI驱动。
- 在PLATINUM Diversity队列中,MACE的独立预测因素包括心源性休克、肾脏疾病、外周血管疾病史、多支病变、丧偶和缺乏私人保险。
临床怎么用
- 对女性和少数族裔PCI患者,除临床和造影因素外,应关注社会健康决定因素(如丧偶、保险状态)以评估1年MACE风险。
- 女性及少数族裔校正后死亡/MI风险更高,主要源于非支架相关MI,提示需加强二级预防和缺血事件监测。
局限性
- PLATINUM Diversity为单臂研究,与PROMUS Element Plus Post-Approval Study为患者水平汇总分析而非随机对照。
- 部分中心重叠,且PROMUS Element Plus Post-Approval Study为all-comers人群,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There exist limited outcomes data for women and minorities after contemporary percutaneous coronary intervention (PCI). OBJECTIVE: To examine 1-year outcomes in women and minorities vs white men after PCI with everolimus-eluting stents. DESIGN, SETTINGS, AND PARTICIPANTS: The PLATINUM Diversity study was a single-arm study enrolling women and minorities. Patient-level pooling with the PROMUS Element Plus Post-Approval Study was prespecified. Data on social determinants of health and language were collected in the PLATINUM Diversity cohort, which included 1501 patients at 52 US sites. The PROMUS Element Plus Post-Approval study enrolled 2681 patients at 52 US sites with some site overlap and included an "all-comers" population. All patients were enrolled beginning in October 2014 and were followed for 12 months. Analyses began in August 2016. INTERVENTIONS: Patients received 1 or more everolimus-eluting stent implantation. MAIN OUTCOMES AND MEASURES: The primary end point was 1-year major adverse cardiac events (MACE), which included death/myocardial infarction (MI)/target vessel revascularization. Secondary ischemic end points were also evaluated. RESULTS: The pooled study consisted of 4182 patients: 1635 white men (39.1%), 1863 women (white and minority) (44.5%), and 1059 minority patients (women and men) (25.3%). Women and minorities had a higher prevalence of diabetes, prior stroke, hypertension, renal disease, and congestive heart failure than white men but lower rates of multivessel disease, prior coronary artery bypass graft surgery, prior MI, and smoking. Unadjusted 1-year MACE rates (white men, 7.6%; women, 8.6%; minorities, 9.6%) were similar between groups with no significant differences after risk adjustment. The adjusted risk of death/MI was higher among women (odds ratio, 1.6; 95% CI, 1.1-2.4) and minorities (odds ratio, 1.9; 95% CI, 1.2-2.8) compared with white men and the adjusted risk of MI was higher in minorities (odds ratio, 2.6; 95% CI, 1.4-4.8). These differences were driven primarily by nonstent-related MIs. Within the PLATINUM Diversity cohort, the independent predictors of MACE were cardiogenic shock, renal disease, history of peripheral vascular disease, multivessel disease, widowhood, and lack of private insurance. CONCLUSIONS AND RELEVANCE: After contemporary everolimus-eluting stent implantation, women and minorities experience a similar risk of 1-year MACE but a higher adjusted risk of recurrent ischemic events primarily because of nonstent-related MIs. Both clinical and angiographic factors and social determinants of health, including widowhood and insurance status, contribute to 1-year MACE among women and minorities.
引用
- Batchelor W, Kandzari DE, Davis S, et al. Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation: Insights and Results From the PLATINUM Diversity and PROMUS Element Plus Post-Approval Study Pooled Analysis. JAMA Cardiol. 2017. PMID: 29049508. doi:10.1001/jamacardio.2017.3802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。